EMA Names Investigational Gene Therapy, BMN 270, a Priority Medicine for Hemophilia A – Hemophilia News Today
|
EMA Names Investigational Gene Therapy, BMN 270, a Priority Medicine for Hemophilia A
Hemophilia News Today BioMarin Pharmaceuticals is moving forward with BMN 270, an experimental gene therapy for the treatment of hemophilia A, and is preparing new clinical trials expected to begin this year. The European Medicines Agency (EMA)'s Committee for Advanced … |
